{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016887","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.585915+00:00","generated_at":"2026-06-24T01:08:57.482162+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AN2 Therapeutics reports Q2 2022 cash of $115.8M, updates on epetraborole trials","bullets":["Cash, cash equivalents and investments $115.8M at June 30, 2022; sufficient to fund operations through mid-2024.","Enrolling U.S. patients in Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease; topline Phase 2 results expected mid-2023.","Completed Phase 1 PK/safety study in Japan; gained PMDA alignment on microbiological primary endpoint for potential registration.","Maggie FitzPatrick appointed to Board of Directors; she previously led public affairs at Johnson & Johnson.","R&D and G&A expenses increased due to higher trial activity and expanded post-IPO operations."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016887","json":"https://secwatch.observer/filing/0000950170-22-016887.json","markdown":"https://secwatch.observer/filing/0000950170-22-016887.md","text":"https://secwatch.observer/filing/0000950170-22-016887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000095017022016887/0000950170-22-016887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000095017022016887/antx-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:08:57.482162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}